Design Therapeutics, Inc.
DSGNNasdaq
$12.57
↓ -0.3%Jul 17 close · end-of-day
Price
1Y↑ +202.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$772.2M
Enterprise Value
$549.4M
P/E
—
P/S
—
P/B
3.5
EV/EBITDA
—
PEG
—
FCF Yield
-7.0%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$69.7M
Free Cash Flow (TTM)
-$54.1M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-32.0%
ROIC
—
Debt / Equity
—
Net Cash
$222.8M
Return 1Y
+212.7%
Company profile
Design Therapeutics, Inc. engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction. It is also developing GeneTAC product candidate portfolio for the. treatment of other monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and
- CEO
- Joao Siffert
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- California
- Website
- designtx.com
Earnings
DSGN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.29↓ -6.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $226,000.00 | — | — | — | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$8.3M | -$35.8M | -$67.6M | -$78.2M | -$62.4M | -$79.5M |
| Net income | -$8.3M | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M |
| Diluted EPS | — | -$0.77 | -$1.14 | -$1.19 | -$0.88 | -$1.22 |
| Operating cash flow | -$8.7M | -$29.4M | -$51.3M | -$58.6M | -$43.1M | -$54.4M |
| Free cash flow | -$8.7M | -$30.9M | -$52.2M | -$58.8M | -$43.4M | -$54.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -3685.8% | — | — | — | — | — |
| Net margin | -3663.7% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.0M | -$16.2M | -$16.7M | -$20.4M | -$21.6M | -$19.3M | -$18.2M | -$19.7M |
| Net income | -$11.8M | -$13.0M | -$13.7M | -$17.7M | -$19.1M | -$17.0M | -$16.0M | -$17.6M |
| Diluted EPS | -$0.21 | -$0.23 | -$0.24 | -$0.31 | -$0.34 | -$0.30 | -$0.27 | -$0.29 |
| Operating cash flow | -$11.3M | -$9.5M | -$9.9M | -$16.8M | -$14.4M | -$11.2M | -$12.0M | -$16.4M |
| Free cash flow | -$11.4M | -$9.6M | -$9.9M | -$16.9M | -$14.5M | -$11.2M | -$12.0M | -$16.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 9, 2026
Jun 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-13 | William Arsani | Sale | 345,000 | $5.25 | $1.8M | filing |
| 2025-08-13 | William Arsani | Sale | 217,627 | $5.25 | $1.1M | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.